Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
accomplish, acquisition, addressing, advantage, afforded, agonist, alleged, apply, applying, assert, attempt, attention, Avenue, aware, back, beneficial, beneficially, biotechnology, blank, breach, bring, brought, Bruce, call, called, canceled, capability, centralized, certainty, certificate, Chairman, charter, check, circumvented, claim, claiming, Code, commonplace, comparison, competitive, competitor, comply, concentration, conservation, conserve, consuming, correct, costly, count, coverage, Delaware, demand, depressing, diminished, discourage, disproportionate, disproportionately, distraction, distribute, distribution, diversion, divert, diverted, division, Dr, Duffy, duly, earliest, economic, efficiently, elucidated, employ, employed, encounter, encountered, erode, exceed, exempt, Exhibit, exploration, extraordinary, extreme, extremely, faced, factual, fail, faith, February, federal, feet, fiduciary, forecast, foreign, Fred, freedom, Friedman, frustrate, gain, Gollust, good, grace, grow, harm, harmed, Hartwell, headcount, HeFH, highlighted, HoFH, hostile, hypercholesterolemia, inadvertently, inclined, influence, infringe, infringed, infringement, infringing, instance, interfere, invalid, invalidated, Keith, Kovner, Kufe, Landlord, lapse, law, lawsuit, learn, lengthy, letter, Lexington, likelihood, located, lose, MA, Madrigal, Marc, maximize, maximizing, meaningful, merge, merger, merging, modest, Morenstein, mutually, NASH, negate, oral, oversight, ownership, Panel, Paul, pendency, percent, perception, pill, point, poison, policy, political, precisely, preferred, premium, printing, prohibit, prohibited, prospective, prospectively, proxy, pursuit, Reardon, Rebecca, recommend, relevant, remedy, remove, renegotiate, renewable, Reorganization, replace, replaced, representation, resolution, restated, resume, return, Robert, RSU, Saffron, Schneebaum, Scott, secret, smaller, soliciting, sooner, spend, spouse, square, stop, subsidiary, suffer, takeover, Taub, taxable, technical, therewith, THR, thyroid, timeframe, timeline, turn, twelve, unauthorized, unenforceable, unknown, unmet, unquantifiable, unrelated, unsolicited, volume, William, Wilson, wind, wrongfully, xx, yearly
Removed:
academic, accelerated, acceleration, accumulation, accurately, achieving, acute, adaptive, adding, advancement, age, aggressive, agile, Alan, AML, animal, antitumor, Antonio, approach, arm, array, assigned, Bansal, bar, Bayesian, bearing, bioavailability, biodistribution, biologically, blast, bone, Boston, breast, Burnett, capecitabine, capitalize, Cardiff, center, Centre, characterized, charge, Chase, choice, cisplatin, clause, College, combine, comparable, comparing, composition, concept, confirmatory, confirmed, considerable, conversion, cooperative, cytarabine, DA, Dana, daunorubicin, deadly, declined, deducting, deliver, delivery, Denmark, Detectable, developed, diagnosed, die, died, differentiated, discontinue, disease, disordered, dozen, durable, duration, eligibility, Emory, emtansine, enable, enabling, enroll, enrolling, equivalent, Europe, evaluable, eventual, evergreen, evolve, expansion, expend, experiencing, experimental, expertise, extended, extension, extensive, facilitate, fallopian, Farber, fashion, Figure, flat, Fox, free, fulvestrant, GALAXY, Genetic, graduate, Group, gynecologic, Haematological, half, heavily, hematopoietic, hold, hormonal, illustrate, immature, Importantly, improve, improved, individual, induce, ineffective, inefficient, initiate, innovative, Institute, intensive, Interestingly, investigation, investigational, irreversible, Kettering, Kingdom, Langone, largest, launch, led, length, lesser, leukemia, leukemic, leverage, locally, London, Lymphoma, marrow, match, MDS, median, Medicine, melanoma, Memorial, mesothelioma, metabolic, MLV, modify, month, MTD, multicenter, myelodysplastic, myeloid, NCRI, negative, neoplasm, neutropenia, nominate, noted, observed, older, pace, pancreatic, partial, PDX, pemetrexed, people, performed, peritoneal, pertuzumab, pharmacological, Philadelphia, pilot, platform, pleural, poor, predefined, preferential, preferentially, preliminary, pretreated, profile, prognostic, progressed, progressing, progression, progressive, projecting, promising, proof, proportion, protocol, provision, quality, quantifiable, ranging, rapid, rapidly, recruitment, rectal, recurrent, regimen, relapsed, remission, remote, request, resigned, resistant, respond, response, restrict, San, Sanjay, SCLC, screen, select, selected, selection, selectively, separation, Serial, show, showing, Sloan, solubility, sponsorship, stable, standing, stem, stimulated, suggesting, suitable, superiority, surgery, Symposium, syndrome, test, tested, testing, therapeutically, thrombocytopenia, tolerate, tolerated, toxicology, traditionally, transporter, trap, trastuzumab, treat, triplet, tube, turnaround, UK, uncontrolled, undergoing, unexpected, unfavorable, unique, University, UT, utilized, variability, vivo, vulnerable, weekly, women, work, World, worldwide, xenograft, York, younger, Zealand
Filing tables
Filing exhibits
MDGL similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATIONS UNDER SECTION 906
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Synta Pharmaceuticals Corp., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:
The Quarterly Report on Form 10-Q for the period ended March 31, 2016 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: May 10, 2016 | /s/ Chen Schor |
| Chen Schor |
| President and Chief Executive Officer |
| (principal executive officer) |
|
|
|
|
Dated: May 10, 2016 | /s/ Marc Schneebaum |
| Marc Schneebaum. |
| Senior Vice President and |
| Chief Financial Officer |
| (principal accounting and financial officer) |
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.